CoChat

G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab

Fiala, Ondrej, Buchler, Tomas, Mohelnikova-Duchonova, Beatrice, Melichar, Bohuslav, Matejka, Vit Martin, Holubec, Lubos, Kulhankova, Jana, Bortlicek, Zbynek, Bartouskova, Marie, Liska, Vaclav, Topolcan, Ondrej, Sedivcova, Monika, Finek, Jindrich · 2016 · Tumor Biology

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Abstract

The v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are found in 35-45 % of colorectal cancer (CRC) cases. Although the association between the RAS signaling and angiogenesis is well known, the negative predictive value of KRAS mutation has not been established in patients treated with bevacizumab. The aim of this study was to evaluate the association between specific KRAS mutation types and outcome of patients with metastatic CRC treated with bevacizumab. The study included 404 patients with metastatic CRC (mCRC) treated with bevacizumab. Clinical data obtained from the clinical registry CORECT were retrospectively analyzed. The shortest survival was observed in patients with tumors harboring G12V or G12A KRAS mutation (G12V/A). The median progression-free survival (PFS) and overall survival (OS) for patients with tumors harboring G12V/A KRAS mutation was 6.6 and 16.8 compared to 11.6 and 26.3 months for patients with tumors harboring other KRAS mutation type (p < 0.001 and p < 0.001), while the survival of patients harboring other KRAS mutation types was comparable to those with tumors harboring wild-type KRAS gene. In the Cox multivariable analysis, KRAS G12V/A mutation type remains a significant factor predicting both PFS (HR = 2.18, p < 0.001) and OS (HR = 2.58, p < 0.001). In conclusion, the results of the present study indicate that there is a significant difference in biological behavior between tumors harboring G12V/A and other KRAS mutations. M…

Overview

Integrity signals

Registry

Crossref · 10.1007/s13277-015-4523-7

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 43 references

Cited by

See all 58

Metadata

Authors
Fiala, O., Buchler, T., Mohelnikova-Duchonova, B., Melichar, B., Matejka, V. M., Holubec, L., Kulhankova, J., Bortlicek, Z., Bartouskova, M., Liska, V., Topolcan, O., Sedivcova, M., & Finek, J.
Affiliations
  • Palacký University Olomouc (CZ)
  • Charles University (CZ)
Venue
Tumor Biology
Published
2015-12-10
Volume
37
Issue
5
Pages
6823-6830
ISSN
  • 1010-4283 (ISSN-L)
  • 1423-0380
OpenAlex
W2464728687
Cited by
55
References
44
Citations by year
2026: 1 · 2025: 8 · 2024: 3 · 2023: 8 · 2022: 3 · 2021: 6 · 2020: 7 · 2019: 10 · 2018: 4 · 2017: 4 · 2016: 1
FWCI
1.31
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Tumor Biology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Ministry of Education Youth and Sports of the Czech Republic (LO1503)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
KRAS mutation, metastatic colorectal cancer, bevacizumab, prognostic factors, progression-free survival, overall survival, Ras signaling, angiogenesis
MeSH terms
Bevacizumab, Adult, Aged, Aged, 80 and over, Alleles, Codon, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Prognosis, Colorectal Neoplasms, Proportional Hazards Models, Treatment Outcome, ras Proteins, Retreatment, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. https://app.cochat.ai/papers/10.1007/s13277-015-4523-7
The paper
Fiala, O., Buchler, T., Mohelnikova-Duchonova, B., Melichar, B., Matejka, V. M., Holubec, L., Kulhankova, J., Bortlicek, Z., Bartouskova, M., Liska, V., Topolcan, O., Sedivcova, M., & Finek, J. (2016). G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumor Biology. https://doi.org/10.1007/s13277-015-4523-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.